ProductLife Group at ISPOR ITALY 2025

ProductLife Group (PLG), together with its affiliate Intexo Società Benefit, takes part in the scientific activities of the ISPOR Italy Conference with contributions that reflect the Group’s commitment to strengthening the evaluation, pricing, and access of health technologies.

PLG-Intexo’s involvement in the national programme underscores an approach grounded in scientific rigour, methodological excellence and continuous attention to the evolution of access frameworks in Italy and across Europe.

In a landscape marked by growing economic, regulatory and societal complexity, PLG-Intexo contributes through:

• solid methodological foundations
• comparative evidence across major European markets
• real-world perspectives from industry and relevant stakeholders

These capabilities support transparent, credible and patient-relevant value assessments and contribute to informed and sustainable decision-making.

The Intexo team is responsible for three scientific posters focusing on key areas of innovation, pricing and comparative assessment:

1. Innovative Medicines in Italy: Reimbursement Beyond Willingness-to-Pay Thresholds

Authors: Daniela Cazzato, Giulia Fagnocchi, Alessia Marocco, Elisa Elena Mariano, Mariangela Prada

2. Clinical and Economic Comparison of Innovative Medicines Across the EU5

Authors: Giulia Fagnocchi, Daniela Cazzato, Alessia Marocco, Elisa Elena Mariano, Mariangela Prada

3. Opportunities and Challenges of the New Italian R-HTA: Industry Perspectives

Authors: Letizia Rossi, Elisa Elena Mariano, Giulia Fagnocchi, Francesca Saviano, Giovanni Callegaro, Michele Barletta, Federica Imbò, Federica Lo Presti, Viola Schiavone, Valentina Tosto,
Eleonora Maria Vadrucci, Mariangela Prada
– Project developed in collaboration with BioPharma Network and Bocconi University –

Together, these studies provide new analytical insights on reimbursement thresholds, comparative approaches across the EU5 and the operational implications of Italy’s evolving R-HTA model.

In addition to the scientific contributions, PLG–Intexo experts have taken part in two ISPOR Italy Rome Chapter working groups addressing foundational topics in Market Access:

• archetypes for drug price evaluation and negotiation
• quality criteria for economic evaluation models supporting pricing decisions

The outputs of these groups—developed in collaboration with academia, institutions and industry—aim to strengthen national methodological standards and promote consistent and transparent decision-making processes.

PLG-Intexo’s engagement in ISPOR activities is an integral part of the Group’s mission to contribute to robust, sustainable and evidence-based approaches to value assessment and access. Through scientific collaboration and continuous knowledge development, PLG supports healthcare stakeholders navigating an increasingly complex environment.

Organisations interested in exploring topics related to pricing, reimbursement, R-HTA implementation or cross-country HTA analysis can contact our team to discuss their needs and potential tailored support.